RESEARCH

Open Access



Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Zhiru Li^{1,2,3†}, Chao Li^{4†}, Dong Yang^{1,2}, Junmei Song^{1,2}, Ting Liu^{1,2}, Ziyan Zhou^{1,2}, Lifang Zhou⁵ and Min Kang^{1,2*}

Abstract

Background: Cisplatin-based concurrent chemoradiotherapy has been identified as the primary and standard treatment for locally advanced nasopharyngeal carcinoma (NPC). However, the side effects of cisplatin affect the compliance to therapy. Thus, the search for a platinum-based substitute for NPC has always been a research focus. However, there is a variability in the efficacy of different platinum-based chemotherapies in the treatment of NPC. We performed a meta-analysis to compare the efficacy and safety of cisplatin-based regimens and other platinum-based derivatives (carboplatin, nedaplatin, and lobaplatin) for locally advanced NPC.

Methods: PubMed, EMBASE, Cochrane Library, Web of Science, and ClinicalTrials.gov were systematically searched for all potentially eligible clinical trials as of February 15, 2022. The pooled hazard ratios, risk ratio, and 95% confidence interval were calculated using Review Manager Software version 5.4.

Results: A total of 1,907 patients with locally advanced NPC were eligible from the 1,265 retrieved records. This systematic review included eight articles, six of which were randomized controlled clinical trials. There was no significant difference in the 3- and 5-year overall survival, progression-free survival, distant metastasis-free survival, and locoregional relapse-free survival between cisplatin-based chemotherapy and other platinum-based chemotherapy. Severe acute hematological side effects (> grade 3) during treatment, such as neutropenia, leukopenia, and thrombocytopenia, were equivalent in both groups. However, the incidence of anemia was higher in patients receiving other platinumbased chemotherapies. The risk of nausea, vomiting and weight loss was higher in the cisplatin group; however, there was no significant difference in the other non-hematological and late side effects between the two groups.

Conclusions: Other types of platinum-based chemotherapies are as effective as cisplatin-based chemotherapy in the treatment of locally advanced NPC, thus acting as potential alternatives to cisplatin. Further studies providing high-level evidence are needed.

[†]Zhiru Li and Chao Li made equal contributions to this study.

*Correspondence: kangmin@gxmu.edu.cn

¹ Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning 530021, Guangxi, People's Republic of China

Full list of author information is available at the end of the article



© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Keywords: Cisplatin, Platinum-based derivatives, Survival, Side effect, NPC, Meta-analysis

Background

The global geographical distribution of nasopharyngeal carcinoma (NPC) is unbalanced, with >70% of the new NPC cases being reported in China and Southeastern Asia. An age-standardized incidence rate between 3.0 and 10.2 per 100,000 people has been reported in China [1, 2]. More than 70% of newly diagnosed NPC cases are classified as locally advanced disease in stages II-IVB [3]. Cisplatin-based concurrent chemoradiotherapy (CCRT) has been identified as the primary and standard treatment for locally advanced NPC. Although cisplatin offers substantial survival benefits to patients [3-5], its limitations lie in the poor adherence to treatment and side effects such as nausea, vomiting, nephrotoxicity, ototoxicity, and neurotoxicity [6, 7]. Therefore, there is an emerging need for other chemotherapeutic agents with similar efficacy against NPC and fewer side effects. Other platinum-based derivatives such as nedaplatin, lobaplatin and carboplatin have similar efficacy and fewer side effects, thus they have been used to replace cisplatin in the treatment of NPC [8-10]. However, no statistically significant results have been obtained from these studies. Thus, the aim of this meta-analysis of published clinical trials, retrospective studies, and paired analyses, was to compare the efficacy and safety of cisplatin-based and other platinum-based regimens in the treatment of locally advanced NPC.

Methods

Search strategy

We conducted a thorough search of the databases of medical publications: PubMed trial, EMBASE, Cochrane Library, Web of Science, and ClinicalTrials.gov, searching for all available records until February 15, 2022. The search was conducted by "subject word" or "title or key word." The search terms included: "Nasopharyngeal carcinoma," "Carcinoma, Nasopharyngeal," "Carcinomas, Nasopharyngeal," "Nasopharyngeal Carcinomas," "Cisplatin," "lobaplatin," "Nedaplatin," "carboplatin," and "randomized controlled trial or Randomized or placebo or RCT." We manually searched the references of relevant articles to retrieve more clinical studies. In addition, a search was conducted before the final analysis. Two researchers (ZL and CL) independently screened the literature from the above databases and selected articles that met the inclusion criteria by reading the title or abstracts. If published data overlapped, only the most current information was included. In addition, a third researcher (DY) intervened to resolve any dispute(s).

Inclusion criteria

All the studies included in this meta-analysis followed the PICOS principles (Participants, Intervention, Comparison and Outcomes, Study design). The details are as follows: (1) P: patients with stage II-IVB locally advanced NPC diagnosed by pathology; (2) I: Patients in the experimental group received chemotherapy with other platinum derivatives (carboplatin, nedaplatin, and lobaplatin), while the control groups received cisplatin chemotherapy. The specific combination of chemotherapy and radiotherapy techniques were ignored in both groups; (3) C: analysis of therapeutic efficacy and toxicity during and after radiotherapy and chemotherapy; (4) O: major positive outcomes include overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), while negative outcomes include hematologic and non-hematologic toxicities; (5) S: we not only included randomized controlled trials, but also observational studies (including cohort and case-control studies).

Exclusion criteria

Studies with any of the following characteristics were excluded: (1) studies on recurrent and metastatic nasopharyngeal carcinoma, (2) studies including patients with prior treatment with immunosuppressants or antiangiogenic drugs, (3) studies lacking detailed information or conference summaries, (4) unpublished studies, (5) single-arm clinical trials.

Data extraction and quality assessment

The following details were extracted from each eligible clinical trial: first author, publication year, inclusion period, registration number, study design, number of patients, tumor stage, mean age, median follow-up period, therapeutic regimens, OS, PFS, DMFS, LRFS, and adverse events.

Two assessment scales were used to assess the methodological quality of each eligible trial. The Cochrane risk bias assessment tool [11] was used to evaluate the quality of included randomized controlled clinical trials (RCTs). The quality evaluation included six aspects: random sequence generation, assignment hiding, blind method implementation, data integrity, reporting bias and other bias. There were three options for each: "low risk," "high risk," or "unclear." The quality of the two retrospective studies was evaluated using the Newcastle–ottawa Scale (NOS) [12], including study population selection, intergroup comparability, and outcome measurements. It was graded by the semi-quantitative principle of the star system, the full score is 9, and \geq 6 is classified as high-quality literature. The final NOS scale defined two retrospective studies as high-quality studies. The two researchers (ZL and CL) independently conducted and cross-checked the above-mentioned literature quality during the evaluation process. In case of any disagreement, the third researcher (DY) was consulted.

Statistical analysis

Summary statistics were compiled using the Review Manager Software, version 5.4 (Cochrane Collaboration RevMan, version 5.4, Oxford, UK). Survival outcomes (OS, PFS, DMFS, and LRFS) were assessed by hazard ratios (HRs) and 95% confidence intervals (CIs). If the HR was not directly described in the paper, Engauge Digitalizer version 4.1 software was used to extract data from the Kaplan-Meier survival curves according to the method of Tierney et al. [13], then the natural logarithm of HR (InHR) and standard error could be calculated. The relative risk (RR) was used to quantify and analyze efficacy. The inverse variance (IV) method was used to evaluate HR, and the Mantel Haenszel method was used to evaluate RR. The X² test and I² statistical and quantitative heterogeneity tests were used in each study, where p < 0.10 or I²>50% indicated that there was heterogeneity in each study and the random effect model was used for analysis. However, p > 0.10 or $I^2 < 50\%$ indicated no statistical heterogeneity (H) and the fixed effect model was used for analysis. Sensitivity analysis excluded any element from the study and observed its impact on the combined statistics and the heterogeneity of test results.

Results

Study selection

A total of 1,265 articles were retrieved from the PubMed, EMBASE, Cochrane Library and Web of Science databases. Two hundred and fifty-two duplicate records were deleted. After screening the title and abstract, there were 19 qualified articles left. After reading the full texts, eight studies [14–22] were finally included in the meta-analysis. The specific process of research screening is shown in Fig. 1.

Eligible studies and characteristics

The eight studies included in this review included a total of 1,907 patients. Six of the eight studies were RCTs, while the other two were retrospective studies. Through the Cochrane bias risk analysis tool, four RCTs [14–18] were noted as having used a random number method and the other two RCTs [21, 22] did not indicate specific random methods. All RCTs included in this study did not explain hidden groups and there was no indication that blinding was applied to patients and doctors.

However, most of the outcome indicators for those RCTs were based on clinical data, and the blinding method has a relatively little impact on the clinical data. All the literature data were complete, where no missing information or incomplete data affected the analysis of the results, and no selective reports or other sources of bias were found in the studies. The details about the risk bias are shown in Fig. 2. The NOS scale defined two retrospective studies as high-quality studies. Table 1 shows the basic characteristics of the eligible clinical trials, while Table 2 shows the details and outcome measures of the treatment regimens.

OS


The 3-year OS data were obtained from three studies with a total of 655 patients (cisplatin group, 328 patients; and other platinum-based chemotherapies group, 327 patients). Forest plots showed that there was no significant difference in the 3-year OS between the two groups (HR, 0.88; 95% CI, [0.70-1.09]; p=0.24; H: $I^2=0\%$, p=0.41). The 5-year OS data were obtained from three studies with a total of 1,090 patients (cisplatin group, 534 patients; and other platinum-based chemotherapies group, 556 patients). There was no significant difference in the 5-year OS between the two groups (HR, 0.97; 95% CI, [0.70-1.35]; p=0.87; H: $I^2=0\%$; p=0.76; Fig. 3).

PFS

The 3-year PFS data were obtained from 449 patients in two studies (cisplatin group, 223 patients; and other platinum-based chemotherapies group: 226 patients). There was no significant difference in the 3-year PFS between the two groups (HR, 1.12; 95% CI, [0.77–1.65]; p=0.55; H: $I^2=0\%$; p=0.91). The 5-year PFS data were obtained from three studies with a total of 1,090 patients (cisplatin group, 534 patients; and other platinum-based chemotherapies group, 556 patients). There was no significant difference in the 5-year PFS between the two groups (HR, 0.99; 95% CI, [0.78–1.27]; p=0.94; H: $I^2=0\%$; p=0.64) (Fig. 4).

DMFS

The 3-year DMFS data were obtained from a total of 655 patients in three studies (cisplatin group, 328 patients; and other platinum-based chemotherapies group, 327 patients). There was no significant difference in the 3-year DMFS between the two groups (HR, 0.95; 95% CI, [0.65–1.38]; p=0.79; H: I²=56%; p=0.11). The 5-year DMFS data were obtained from 1,090 patients in three studies (cisplatin group, 534 patients; and other platinum-based chemotherapies group, 556 patients).



There was no significant difference in the 5-year DMFS between the two groups (HR, 0.78; 95% CI, [0.57–1.07]; p = 0.12; H: I² = 0%; p = 0.96) (Fig. 5).


LRFS

The 3-year LRFS data were obtained from a total of 449 patients in two studies (cisplatin group, 223 patients; and other platinum-based chemotherapies group, 226 patients). There was no significant difference in the 3-year LRFS between the two groups (HR, 1.02; 95% CI, [0.97-1.07]; p=0.47; H: $I^2=0\%$; p=0.51). The 5-year LRFS data were obtained from three studies with a total of 1,090 patients (cisplatin group, 534 patients; and other platinum-based chemotherapies group, 556 patients). There was no significant difference in the 5-year LRFS between the two groups (HR, 1.13; 95% CI, [0.78-1.63]; p=0.51; H: $I^2=26\%$; p=0.26) (Fig. 6).

Grade \geq 3 acute toxicities

Based on acute grade 3 or higher acute toxicities during treatment in the other platinum-based chemotherapies and cisplatin groups, the following risks were calculated. With regard to hematological toxicities, there was no significant difference in the risk of neutropenia (RR, 1.21; 95% CI, [0.94–1.57]; p=0.14), leukopenia (RR, 0.97; 95% CI, [0.81–1.17]; p=0.78), or thrombocytopenia (RR, 1.62; 95% CI, [0.98–2.69]; p=0.06) between the other platinum-based chemotherapies group and the cisplatin group. However, the risk of anemia in the other platinum-based chemotherapies group was significantly higher than that of the cisplatin group (RR, 0.30; 95% CI, [0.12–0.77]; p=0.01).

With regard to non-hematological toxicities, there was no significant difference in the risk of xerostomia (RR, 0.83; 95% CI, [0.51–1.35]; p=0.46),



dermatitis (RR, 1.02; 95% CI, [0.58-1.81]; p=0.95), mucositis (RR, 1.02; 95% CI, [0.58-1.81]; p=0.95), or elevated levels of aminotransferase (RR, 0.71; 95% CI, [0.25-2.05], p=0.53) between the other platinum-based chemotherapies group and the cisplatin group. However, the risk of nausea (RR, 0.12; 95% CI, [0.06-0.25]; p<0.0001), vomiting (RR, 0.15; 95% CI, [0.06-0.40]; p=0.0001), and weight loss (RR, 0.34; 95% CI, [0.12-0.98], p=0.04) were significantly lower in the other platinum-based chemotherapies group than those in the cisplatin group (Table 3).

Treatment-related late toxicities

Based on the late adverse events during the treatment with other platinum derivatives and cisplatin, there was

Study	Inclusion period Register	Register	Type of study Phase	Phase	chemoradiotherapy No.Patients	No.Patients	No.male	No.male Mean Age (Exp/con)	AJCC Stage	Median follow- up(year)
Lv et al	2013-2015	ChiCTR-TRC-13003285	RCT	=	IC + CCRT	502	362	43.5/44	III-IVB	75.3
Tang et al	2011-2012	NCT 01479504	RCT	≡	IC + CCRT	223	NR	45.1/45.3	NI−III	35.1
Linquan et al	2012-2014	NCT01540136	RCT	≡	CCRT	402	302	44/45	II–IVB	47
Hu et al	2014-2015	NR	RCT	=	IC	62	45	50.2/49.8	NI−II	NR
Liu et al	2009–2011	NR	RE	ΞĿ	IC + CCRT	186	119	NR	II–IVB	68
Zhan et al	2012-2017	NR	RE	ΞĿ	IC + CCRT	226	184	NR	AVI-III	39.5
Cao et al	2009-2010	NR	RCT	≡	IC	100	NR	NR	AVI-III	NR
Imjai et al	1999–2004	NR	RCT	=	CCRT + AC	206	126	50/46	III–IVB	26.3

 Table 1
 Characteristics of the eligible studies


group), NA not available, Re retrospetive study, NR not reported, FE fail to extract

Exp v Lv et al Lob 3 m ² d							
	Exp vs con	Exp vs con		Exp/con	Exp/con	Exp/con	Exp/con
DDP 5,eve	Lob 30 mg/m ² d1,22 + 5FU 800 mg/ m ² d1–5,every 21 days for 2cycles vs DDP 100 mg/m ² + 5FU 800 mg/m ² d1 – 5,every 21 days for 2cycles	Lob 30 mg/m² 2 cycles vs DDP 100 mg/m² 2 cycles	IMRT	5 year: 88.2%/89%	75%/75.5%	86.6%/85%	87.7%/88.8%
Tang et al Doci d1, e 65 m é5 m	Doc 65 mg/m2 d1 + Ned 80 mg/m2 d1, every 21 days for 2cycles vs Doc 65 mg/m2 d1 + DDP 80 mg/m2 d1, every 21 days for 2cycles	Ned 40 mg/m2 every week for 3cycles IMRT vs DDP 40 mg /m2 every week for 3cycles	IMRT	3 year: 87.5%/85.9%	3 year: 87.5%/85.9% 3 year: 77.5%/74.9% 3 year: 86.7%/85.1% 3 year: 91.9%/91.7%	3 year: 86.7%/85.1%	3 year: 91.9%/91.7%
Linquan et al NR		Ned 100 mg/m ² d1 every 21 days for 3cycles vs DDP 100 mg/m ² every 21 days for 3cycles	IMRT	5 year: 88.8%/89.4%	2 year: 88.0%/89.9% 5 year: 79.8%/81.4%	5 year: 90.4%/85.9% 5 year: 89.6%/92.6%	5 year: 89.6%/92.6%
Liu et al DDP m ² d' Ned every	DDP 75 mg/m2 d1 + 5FU 800 mg/ Ned 75 mg/m²d1 every 21 days fo m²d1-5, every 21 days for 2-3 cycles vs 2cycles vs DDP 80 mg/m²d1 every Ned 75 mg/m² + 5FU 800 mg/m²d1-5, 21 days for 2cycles every 21 days for 2-3 cycles	Ned 75 mg/m²d1 every 21 days for 2cycles vs DDP 80 mg/m²d1 every 21 days for 2cycles	IMRT	3 year: 82.4%/79.4%	3 year: 82.4%/79.4% 3 year: 72.6%/68.7% 3 year: 80.7%/77.0% 3 year: 86.2%/92.6%	3 year: 80.7%/77.0%	3 year: 86.2%/92.6%
Zhan et al Doc 60–7 m2, c	Doc 60–75 mg/m2 d1 + DDP 60–75 mg/m2 d1 + 5FU 500–600 mg/ m2, d1–5, every 21 days for 1–4 cycles	Ned 80 mg/m2 d1, every 21 days orNed 30 mg/m2 d1 every week vs DDP 80 mg/m2 d1,every 21 days or DDP 30 mg/m2 d1 every week	IMRT	3 year: 90.7%/92.3%	3 year: 90.7%/92.3% 3 year: 78.9%/79.4% 3 year: 82.4%/85.1% 3 year: 96.1%/93.3%	3 year: 82.4%/85.1%	3 year: 96.1%/93.3%
Imjai et al NR		CBP 100 mg/m2 every week vs DDP 100 mg/m ² d1 every 21 days for 3cycles	2D-CRT	3 year: 77.7%/79.2%	NR	3 year: 63.4%/60.9%	NR

Table 2 Therapeutic regimens, survival outcomes in eligible studies

tree regional relapse-i Ę vival, sur ŝ sur P essive rs Progr /IVal, 5 3 È carbopi E E Ë, cispi 200 2021 *5FU* 5-fluorouracil, *Lob* lobaplatin, survival, *FE* fail to extract

A.3year overall survival	l			Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
Imjai 2007	-0.18632958	0.12040454	87.9%	0.83 [0.66, 1.05]	
Tang 2016	0.13102826	0.52608396	4.6%	1.14 [0.41, 3.20]	
Zhan 2020	0.3435897	0.41218547	7.5%	1.41 [0.63, 3.16]	
Total (95% CI)			100.0%	0.88 [0.70, 1.09]	•
Heterogeneity: Chi ² = 1	.78, df = 2 (P = 0.41)); I² = 0%		I	- $ -$
Test for overall effect: Z	Z = 1.17 (P = 0.24)				0.01 0.1 1 10 100 r platinum drugs cisplatin
_					
B.5year overall survival				Hazard Ratio	Hazard Ratio
B.5year overall survival Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Hazard Ratio IV, Fixed, 95% Cl
	log[Hazard Ratio]	SE 0.28409443			
Study or Subgroup	log[Hazard Ratio]	a set a los a los a los a		IV, Fixed, 95% CI	
Study or Subgroup Linquan 2018	log[Hazard Ratio] 0.13976194	0.28409443 0.38651205	35.0% 18.9%	IV. Fixed, 95% Cl 1.15 [0.66, 2.01]	
<u>Study or Subgroup</u> Linquan 2018 Liu 2018	log[Hazard Ratio] 0.13976194 -0.15082289	0.28409443 0.38651205	35.0% 18.9%	IV, Fixed, 95% Cl 1.15 [0.66, 2.01] 0.86 [0.40, 1.83]	
<u>Study or Subgroup</u> Linquan 2018 Liu 2018 Lv 2021	log[Hazard Ratio] 0.13976194 -0.15082289 -0.10536052	0.28409443 0.38651205 0.24729606	35.0% 18.9% 46.1%	IV. Fixed, 95% Cl 1.15 [0.66, 2.01] 0.86 [0.40, 1.83] 0.90 [0.55, 1.46] 0.97 [0.70, 1.35]	IV, Fixed, 95% CI
<u>Study or Subgroup</u> Linquan 2018 Liu 2018 Lv 2021 Total (95% CI)	log[Hazard Ratio] 0.13976194 -0.15082289 -0.10536052 .55, df = 2 (P = 0.76)	0.28409443 0.38651205 0.24729606	35.0% 18.9% 46.1%	IV. Fixed, 95% Cl 1.15 [0.66, 2.01] 0.86 [0.40, 1.83] 0.90 [0.55, 1.46] 0.97 [0.70, 1.35]	




no significant difference between the two groups regarding the risk of xerostomia (RR, 0.96; 95% CI, [0.88–1.05]; p=0.40), subcutaneous fibrosis (RR, 0.95; 95% CI, [0.83–1.08]; p=0.42), hearing impairment (RR, 0.91; 95% CI, [0.64–1.31]; p=0.62), trismus (RR, 0.70; 95% CI, [0.45–1.07]; p=0.10), cranial nerve palsy (RR, 0.83; 95% CI, [0.57–1.20], *p* = 0.32), or temporal lobe necrosis (RR, 0.80; 95% CI, [0.51–1.25]; *p* = 0.32) (Fig. 7).

Subgroup and sensitivity analyses

Two studies reported the efficacy and side effects of induction chemotherapy alone [18, 21], so these two outcomes were analyzed separately. After induction

A. 3year distant metasta	sis-free survival			Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Imjai 2007	-0.35667494	0.17166951	40.8%	0.70 [0.50, 0.98]	-
Tang 2016	0.13102826	0.19791809	36.9%	1.14 [0.77, 1.68]	
Zhan 2020	0.20701417	0.32237042	22.3%	1.23 [0.65, 2.31]	
Total (95% CI)			100.0%	0.95 [0.65, 1.38]	•
Heterogeneity: Tau ² = 0	0.06; Chi² = 4.50, df =	= 2 (P = 0.11);	l² = 56%		
Test for overall effect: 2	Z = 0.27 (P = 0.79)			oth	0.01 0.1 1 10 100 er platinum drugs cisplatin
B. 5year distant metasta	sis-free survival			Hazard Ratio	Hazard Ratio
B. 5year distant metasta <u>Study or Subgroup</u>	sis-free survival log[Hazard Ratio]	SE	Weight		Hazard Ratio IV, Fixed, 95% Cl
	log[Hazard Ratio]	I <u>SE</u> 0.27240832	-	IV, Fixed, 95% CI	
Study or Subgroup	log[Hazard Ratio]	0.27240832	34.5%	IV, Fixed, 95% Cl 0.75 [0.44, 1.28]	
Study or Subgroup Linquan 2018	log[Hazard Ratio] -0.28768207 -0.28768207	0.27240832	34.5% 19.5%	IV, Fixed, 95% Cl 0.75 [0.44, 1.28] 0.75 [0.37, 1.53]	
<u>Study or Subgroup</u> Linquan 2018 Liu 2018	log[Hazard Ratio] -0.28768207 -0.28768207	0.27240832 0.36212245	34.5% 19.5%	IV. Fixed. 95% CI 0.75 [0.44, 1.28] 0.75 [0.37, 1.53] 0.82 [0.52, 1.30]	
<u>Study or Subgroup</u> Linquan 2018 Liu 2018 Lv 2021	log[Hazard Ratio] -0.28768207 -0.28768207 -0.19845094	0.27240832 0.36212245 0.23570245	34.5% 19.5% 46.0%	IV. Fixed. 95% CI 0.75 [0.44, 1.28] 0.75 [0.37, 1.53] 0.82 [0.52, 1.30] 0.78 [0.57, 1.07]	IV, Fixed, 95% Cl
<u>Study or Subgroup</u> Linquan 2018 Liu 2018 Lv 2021 Total (95% CI)	log[Hazard Ratio] -0.28768207 -0.28768207 -0.19845094 0.08, df = 2 (P = 0.96	0.27240832 0.36212245 0.23570245	34.5% 19.5% 46.0%	IV. Fixed. 95% CI 0.75 [0.44, 1.28] 0.75 [0.37, 1.53] 0.82 [0.52, 1.30] 0.78 [0.57, 1.07]	IV, Fixed, 95% Cl
<u>Study or Subgroup</u> Linquan 2018 Liu 2018 Lv 2021 Total (95% CI) Heterogeneity: Chi ² = 0	log[Hazard Ratio] -0.28768207 -0.28768207 -0.19845094 0.08, df = 2 (P = 0.96 Z = 1.54 (P = 0.12)	0.27240832 0.36212245 0.23570245 6); l ² = 0%	34.5% 19.5% 46.0% 100.0%	IV. Fixed. 95% CI 0.75 [0.44, 1.28] 0.75 [0.37, 1.53] 0.82 [0.52, 1.30] 0.78 [0.57, 1.07]	IV, Fixed, 95% Cl 0.01 0.1 1 10 100 r platinum drugs cisplatin



chemotherapy, there was no significant difference in complete response (RR, 1.24; 95% CI, [0.88–1.75.08]; p=0.21) or partial response (RR, 1.25; 95% CI, [0.97–1.62]; p=0.09) between the other platinum-based chemotherapies group and the cisplatin group. There was also no significant difference in the risk of leukocytopenia (RR, 1.06; 95% CI, [0.53–2.12]; p=0.86)

or thrombocytopenia (RR, 0.67; 95% CI, [0.22–2.09]; p=0.49) between the two groups. However, the risk of anemia (RR, 0.47; 95% CI, [0.28–0.80]; p=0.005) was significantly higher in the other platinum-based chemotherapies group than that of the cisplatin group. Moreover, the incidence of vomiting (RR, 0.24; 95% CI, [0.12–0.49]; p<0.0001) in the cisplatin group was

Advese event (grade3-4)	Availabilit	y		Effect		Heter	ogeneity	Analysis model
	Trials (N)	Other platinum (events/total)	Cisplatin (events/ total)	RR (95% CI)	<i>P</i> value	l ²	<i>P</i> value	
Hematological								
neutropenia	5	210/781	169/753	1.21(0.94–1.57)	0.14	53%	0.07	Random effect
leucopenia	5	177/773	173/744	0.97(0.81-1.17)	0.78	45%	0.12	Fixed effect
thrombocytopenia	6	88/886	56/854	1.62(0.98–2.69)	0.06	51%	0.07	Random effect
anemia	5	26/783	77/771	0.30(0.12-0.77)	0.01	72%	0.007	Random effect
Nonhematologic								
xerostomia	5	28/773	33/741	0.83(0.51-1.35)	0.46	0%	0.48	Fixed effect
dermatitis	4	24/573	22/543	1.02(0.58–1.81)	0.95	0%	0.4	Fixed effect
mucositis	6	211/886	227/854	0.91(0.78–1.06)	0.23	27%	0.24	Fixed effect
nausea	3	8/555	62/530	0.12(0.06-0.25)	< 0.0001	0%	0.41	Fixed effect
vomiting	5	22/781	125/753	0.15(0.06-0.40)	0.0001	61%	0.04	Random effect
weight loss	3	4/468	12/445	0.34(0.12-0.98)	0.05	30%	0.24	Fixed effect
Elevation of aminotransferase	2	6/135	7/114	0.71(0.25-2.05)	0.53	0%	0.81	Fixed effect

 Table 3
 Grade 3–4 acute toxicities during treatment

significantly higher than that of the other platinumbased chemotherapies group. The sensitivity analysis showed that the aggregated results at all endpoints remained unchanged when any study was deleted, indicating that the results of this meta-analysis are reliable (Fig. 8).

Discussion

The study showed that the other platinum-based chemotherapy alternatives did not reduce survival and did not significantly increase the incidence of hematological and non-hematological side effects compared with cisplatin-based chemotherapy. To the best of our knowledge, this is the first meta-analysis to examine the efficacy and side effects of cisplatin versus other platinum-based chemotherapies in locally advanced NPC.

In the past 20 years, three major advances have significantly improved the prognosis of patients with NPC. First, intensity-modulated radiation therapy can cover the target area and the local expansion area with good precision. Intensity-modulated radiation therapy can better protect the adjacent normal tissue, especially for patients whose tumors extend backward to the cranial nerve [23, 24]. Second, the combination of cisplatin-based CCRT, induction chemotherapy, or adjuvant chemotherapy effectively improves the survival rate and disease control of NPC [3, 5, 25–27]. Third, the use of advanced imaging techniques, especially the application of MRI and PET-CT, can better evaluate the local and distant invasion of the tumor, which is very critical for the accurate application of intensitymodulated radiation therapy. However, cisplatin-based chemotherapy regimens are known to increase the acute and late toxicities of radiotherapy [16]. Long-term side effects such as nausea, vomiting, auditory function, renal function, or effects on peripheral nerves caused by cisplatin may affect the quality of life of survivors. Moreover, cisplatin-based CCRT requires pretreatment and post-treatment hydration during cisplatin administration to protect the kidneys, which can prolong the hospital stay [14, 16, 17].

Carboplatin, nedaplatin, and lobaplatin were successively included in the study as cisplatin substitutes to improve the compliance of patients, reduce the side effects of chemotherapy and meet the clinical needs. A randomized non-inferiority trial showed that there was no difference between carboplatin-based CCRT and a cisplatin-based regimen in patients with locally advanced NPC. Moreover, carboplatin showed better tolerance in patients with locally advanced NPC [22]. Two other trials indicated that carboplatin induction chemotherapy combined with CCRT did not improve survival in patients with locally advanced NPC compared with carboplatin induction chemotherapy combined with radiotherapy alone [9]. In addition, carboplatin was less effective than cisplatin when given during CCRT in patients with borderline renal function [28].

Nedaplatin, a cisplatin analog, has antitumor mechanism and therapeutic effects similar to that of cisplatin and does not require hydration to protect the kidneys. Two Phase 2 studies have shown that nedaplatin in combination with fluorouracil or docetaxel has an inductive

A. Xerostomia <u>Study or Subgroup</u>	other platinum Events	-	cispla Events		Weight	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% Cl
Imjai 2007	74	96	73	84		0.89 [0.77, 1.02]	-
Linguan 2018	107	200	112	198		0.95 [0.79, 1.13]	•
Tang 2016	97	113	90	110		1.05 [0.93, 1.18]	•
Total (95% CI)		409		392	100.0%	0.96 [0.88, 1.05]	
Total events	278		275				
Heterogeneity: Chi ² =	3.53. df = 2 (P = 0	.17): ² =	43%				
Test for overall effect:						othe	0.01 0.1 1 10 100 er platinum drugs cisplatin
B. Subcutaneous fibrosi	s other platinum	drugs	cispla	tin		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Imjai 2007	55	96	56	84	29.7%	0.86 [0.68, 1.08]	•
Linguan 2018	67	200	71	198	35.5%	0.93 [0.71, 1.22]	+
Tang 2016	73	113	69	110	34.8%	1.03 [0.84, 1.26]	•
Total (95% CI)		409		392	100.0%	0.95 [0.83, 1.08]	•
Total events	195		196				
Heterogeneity: Chi ² =			0%				0.01 0.1 1 10 100
Test for overall effect:	Z = 0.81 (P = 0.42	2)				othe	er platinum drugs cisplatin
C. Hearing impairmer		-	cisplati			Risk Ratio	Risk Ratio
Study or Subgroup						M-H, Random, 95% C	
Linquan 2018	61	200	77	198	59.4%	0.78 [0.60, 1.03]	_
Tang 2016	34	113	29	110	40.6%	1.14 [0.75, 1.74]	T
Total (95% CI)		313		308	100.0%	0.91 [0.64, 1.31]	
Total events	95		106				
Test for overall effect: D. Trismus	Z = 0.49 (P = 0.62) other platinum		cispla	tin		oth Risk Ratio	0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Linquan 2018	24	200	36	198	81.7%		
Tang 2016		200	00	100	01.770	0.66 [0.41, 1.06]	-
0	7	113	8	110		0.66 [0.41, 1.06] 0.85 [0.32, 2.27]	
Total (95% CI)			8	110		• • •	•
Total (95% CI) Total events	31	113 313	8	110	18.3%	0.85 [0.32, 2.27]	•
Total (95% CI)	31 0.21, df = 1 (P = 0	113 313 .65); I ² =	8	110	18.3%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07]	0.01 0.1 1 10 100
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10	113 313 .65); I ² = -	8 44 0%	110 308	18.3%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe	er platinum drugs cisplatin
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum	113 313 .65); I ² = -)) drugs	8 44 0% cispla	110 308 tin	18.3% 100.0%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u>	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum Events	113 313 .65); I ² = -)) drugs Total	8 44 0% cispla <u>Events</u>	110 308 tin <u>Total</u>	18.3% 100.0% <u>Weight</u>	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio M-H. Fixed, 95% CI	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum <u>Events</u> 40	113 313 65); l ² = - 0) drugs <u>Total</u> 200	8 44 0% cispla <u>Events</u> 47	110 308 tin <u>Total</u> 198	18.3% 100.0% <u>Weight</u> 95.9%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22]	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u>	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum Events	113 313 .65); I ² = -)) drugs Total	8 44 0% cispla <u>Events</u>	110 308 tin <u>Total</u>	18.3% 100.0% <u>Weight</u> 95.9%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio M-H. Fixed, 95% CI	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% CI)	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum <u>Events</u> 40 1	113 313 65); l ² = - 0) drugs <u>Total</u> 200	8 44 0% cispla <u>Events</u> 47 2	110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22]	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% CI) Total events	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum <u>Events</u> 40 1	113 313 .65); l ² = -)) drugs Total 200 113 313	8 44 0% cispla <u>Events</u> 47 2 49	110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9% 4.1%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22] 0.49 [0.04, 5.29]	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% CI)	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10) other platinum Events 40 1 0.20, df = 1 (P = 0)	113 313 .65); l ² = -)) drugs Total 200 113 313 .66); l ² = -	8 44 0% cispla <u>Events</u> 47 2 49	110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9% 4.1%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20]	er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10) other platinum Events 40 1 0.20, df = 1 (P = 0 Z = 1.00 (P = 0.32)	113 313 .65); ² = -)) drugs Total 200 113 313 .66); ² = - 2)	8 44 0% cispla <u>Events</u> 47 2 49	110 308 tin Total 198 110 308	18.3% 100.0% <u>Weight</u> 95.9% 4.1%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% CI 0.01 0.1 1 10 100
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10) other platinum Events 40 1 0.20, df = 1 (P = 0 Z = 1.00 (P = 0.32)	113 313 .65); ² = -)) drugs Total 200 113 313 .66); ² = - 2)	8 44 0% cispla <u>Events</u> 47 2 49 0% 0%	110 308 tin Total 198 110 308 tin	18.3% 100.0% <u>Weight</u> 95.9% 4.1%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio	er platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio
Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy Study or Subgroup Linquan 2018 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: F. Temporal lobe necros	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum Events 40 1 0.20, df = 1 (P = 0 Z = 1.00 (P = 0.32 is other platinum	113 313 .65); ² = -)) drugs Total 200 113 313 .66); ² = - 2) drugs	8 44 0% cispla <u>Events</u> 47 2 49 0% 0%	110 308 tin Total 198 110 308 tin	18.3% 100.0% Weight 95.9% 4.1% 100.0% Weight	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H. Fixed, 95% CI</u> 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio	er platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: F. Temporal lobe necros <u>Study or Subgroup</u>	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum Events 40 1 0.20, df = 1 (P = 0 Z = 1.00 (P = 0.32 is other platinum Events	113 313 .65); ² = -)) drugs Total 200 113 313 .66); ² = - 2) drugs Total	8 44 0% cispla <u>Events</u> 47 2 49 0% cispla <u>Events</u>	110 308 tin Total 198 110 308 tin Total	18.3% 100.0% <u>Weight</u> 95.9% 4.1% 100.0% <u>Weight</u> 91.6%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio <u>M-H, Fixed, 95% CI</u>	er platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio
Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: F. Temporal lobe necros <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% Cl)	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum <u>Events</u> 40 1 	113 313 .65); $ ^2 = 1$)) drugs Total 200 113 313 .66); $ ^2 = 1$ 2) drugs Total 200 123 200 200	8 44 0% cispla <u>Events</u> 47 2 49 0% cispla <u>Events</u> 33 3 3	110 308 tin 198 110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9% 4.1% 100.0% <u>Weight</u> 91.6%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio M-H. Fixed, 95% CI 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio M-H. Fixed, 95% CI 0.84 [0.53, 1.34] 0.32 [0.03, 3.07]	er platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio
Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: F. Temporal lobe necros <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% Cl) Total (95% Cl) Total events	31 0.21, df = 1 (P = 0) Z = 1.66 (P = 0.10) other platinum <u>Events</u> 40 1 41 0.20, df = 1 (P = 0) Z = 1.00 (P = 0.32) is other platinum <u>Events</u> 28 1	113 313 .65); ² = -)) drugs Total 200 113 313 .66); ² = - 2) drugs Total 200 113 313 .66); ² = -	8 44 cispla <u>Events</u> 47 2 49 0% cispla <u>Events</u> 33 3 3	110 308 tin 198 110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9% 4.1% 100.0% <u>Weight</u> 91.6% 8.4%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio M-H. Fixed. 95% CI 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio M-H. Fixed. 95% CI 0.84 [0.53, 1.34] 0.32 [0.03, 3.07]	er platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio
Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: E. Cranial nerve palsy <u>Study or Subgroup</u> Linquan 2018 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: F. Temporal lobe necros <u>Study or Subgroup</u> Linquan 2018 Tang 2016 Total (95% Cl)	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum Events 40 1 0.20, df = 1 (P = 0 Z = 1.00 (P = 0.32 is other platinum Events 28 1 29 0.66, df = 1 (P = 0	113 313 $(.65); 2 = -)$ 100 100 113 313 $(.66); 2 = -)$ 100 113 200 113 200 113 313 313 $(.42); 2 = -)$	8 44 cispla <u>Events</u> 47 2 49 0% cispla <u>Events</u> 33 3 3	110 308 tin 198 110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9% 4.1% 100.0% <u>Weight</u> 91.6% 8.4%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio M-H. Fixed, 95% CI 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio M-H. Fixed, 95% CI 0.84 [0.53, 1.34] 0.32 [0.03, 3.07] 0.80 [0.51, 1.25]	r platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 r platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100
Total (95% CI) Total events Heterogeneity: Chi² = Test for overall effect: E. Cranial nerve palsy Study or Subgroup Linquan 2018 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi² = Test for overall effect: F. Temporal lobe necros Study or Subgroup Linquan 2018 Tang 2016 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneity: Chi² =	31 0.21, df = 1 (P = 0 Z = 1.66 (P = 0.10 other platinum Events 40 1 0.20, df = 1 (P = 0 Z = 1.00 (P = 0.32 is other platinum Events 28 1 29 0.66, df = 1 (P = 0	113 313 $(.65); 2 = -)$ 100 100 113 313 $(.66); 2 = -)$ 100 113 200 113 200 113 313 313 $(.42); 2 = -)$	8 44 cispla <u>Events</u> 47 2 49 0% cispla <u>Events</u> 33 3 3	110 308 tin 198 110 308 tin Total 198 110	18.3% 100.0% <u>Weight</u> 95.9% 4.1% 100.0% <u>Weight</u> 91.6% 8.4%	0.85 [0.32, 2.27] 0.70 [0.45, 1.07] othe Risk Ratio M-H. Fixed, 95% CI 0.84 [0.58, 1.22] 0.49 [0.04, 5.29] 0.83 [0.57, 1.20] othe Risk Ratio M-H. Fixed, 95% CI 0.84 [0.53, 1.34] 0.32 [0.03, 3.07] 0.80 [0.51, 1.25]	er platinum drugs cisplatin Risk Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 10 100 er platinum drugs cisplatin Risk Ratio M-H. Fixed. 95% Cl

	. CR Study or Subgroup	other platinum Events	drugs Total	cispla Events		Weight	Risk Ratio <u>M-H. Random, 95% C</u>	Risk Ratio I M-H. Random, 95% CI	
	Cao 2011	36	50	32	50	74.1%	1.13 [0.86, 1.47]		
	Hu 2016	17	32	10	31	25.9%	1.65 [0.90, 3.02]		
	Total (95% CI)		82		81	100.0%	1.24 [0.88, 1.75]	•	
	Total events	53		42					
	Heterogeneity: Tau ² =	0.02; Chi ² = 1.38,	df = 1 (P	= 0.24); I	² = 28%				
	Test for overall effect:	Z = 1.24 (P = 0.21)				oth	0.01 0.1 1 10 her platinum drugs cisplatin	100
В	. PR	other platinum	drugs	cispl	atin		Risk Ratio	Risk Ratio	
	Study or Subgroup	Events	Total	Events	s Tota	l Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
	Cao 2011	36	50	32	2 50	75.9%	1.13 [0.86, 1.47]		
	Hu 2016	17	32	10			1.65 [0.90, 3.02]	+ - -	
]		
	Total (95% CI)		82		81	100.0%	1.25 [0.97, 1.62]	•	
	Total events	53		42	,		• • •		
	Heterogeneity: Chi ² =		(24): ² =		-			H H H	— I
	Test for overall effect:	, ,		_0,0				0.01 0.1 1 10	100
	. cot los ovorall ellebt.		- /				othe	er platinum drugs cisplatin	
\boldsymbol{C}	Leucopenia	other platinum	druge	cispl	atin		Risk Ratio	Risk Ratio	
\mathbf{C}	Study or Subgroup	Events	-			Woight	M-H, Fixed, 95% Cl		
-						-			
	Hu 2016	3	32	4			0.73 [0.18, 2.99]		
	Zhan 2020	12	113	10) 113	3 71.1%	1.20 [0.54, 2.66]		
	Total (95% CI)		145		111	100.0%	1.06 [0.53, 2.12]	•	
		45	145			100.076	1.00 [0.55, 2.12]	Ť	
	Total events	15	E 4) 12	14	ł				
	Heterogeneity: Chi ² =	, (0%				0.01 0.1 1 10	100
	Test for overall effect:	Z = 0.17 (P = 0.86)	5)				othe	er platinum drugs cisplatin	
-									
	. Thrombocytopenia	other platinum	drugs	cispl	atin		Risk Ratio	Risk Ratio	
_	Study or Subgroup	Events	Total	Events	s Tota	l Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI	
	Hu 2016	4	32	5	5 31	77.2%	0.78 [0.23, 2.62]		
	Zhan 2020	0	113	1	113	3 22.8%	0.33 [0.01, 8.10]		
	Total (95% CI)		145		144	100.0%	0.67 [0.22, 2.09]		
	Total events	4		6	6				
				0%					
	Heterogeneity: Chi ² =	, ,							100
	Heterogeneity: Chi ² = Test for overall effect:	, ,					othe	0.01 0.1 1 10 er platinum drugs cisplatin	100
F	Test for overall effect:	Z = 0.68 (P = 0.49	9)	aianl	otin			er platinum drugs cisplatin	100
	Test for overall effect: Anemia	Z = 0.68 (P = 0.49 other platinum) drugs	cispl		l Moight	Risk Ratio	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia Study or Subgroup	Z = 0.68 (P = 0.49 other platinum Events) drugs Total	Events	s Tota		Risk Ratio M-H, Fixed, 95% Cl	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011	Z = 0.68 (P = 0.49 other platinum Events 1	drugs Total 50	Events	<u>s Tota</u> 50	2.8%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 1.00 [0.06, 15.55]	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia Study or Subgroup	Z = 0.68 (P = 0.49 other platinum Events) drugs Total	Events	<u>s Tota</u> 50	2.8%	Risk Ratio M-H, Fixed, 95% Cl	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016	Z = 0.68 (P = 0.49 other platinum Events 1	9) drugs <u>Total</u> 50 113	Events	<u>s Tota</u> 50 110) 2.8%) 97.2%	Risk Ratio <u>M-H. Fixed, 95% Cl</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78]	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI)	Z = 0.68 (P = 0.49 other platinum <u>Events</u> 1 16	drugs Total 50	Events 1 34	<u>s Tota</u> 50 110 160	2.8%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 1.00 [0.06, 15.55]	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events	Z = 0.68 (P = 0.49 other platinum <u>Events</u> 1 16 17	 drugs Total 50 113 163 	Events 1 34 35	<u>s Tota</u> 50 110 160) 2.8%) 97.2%	Risk Ratio <u>M-H. Fixed, 95% Cl</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78]	er platinum drugs cisplatin Risk Ratio	100
	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² =	Z = 0.68 (P = 0.49 other platinum <u>Events</u> 1 16 17 0.30, df = 1 (P = 0	e) drugs <u>Total</u> 50 113 163 163	Events 1 34 35	<u>s Tota</u> 50 110 160) 2.8%) 97.2%	Risk Ratio <u>M-H. Fixed, 95% Cl</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl	
	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events	Z = 0.68 (P = 0.49 other platinum <u>Events</u> 1 16 17 0.30, df = 1 (P = 0	e) drugs <u>Total</u> 50 113 163 163	Events 1 34 35	<u>s Tota</u> 50 110 160) 2.8%) 97.2%	Risk Ratio <u>M-H. Fixed, 95% Cl</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl	100 100
	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² =	Z = 0.68 (P = 0.49 other platinum <u>Events</u> 1 16 17 0.30, df = 1 (P = 0	e) drugs <u>Total</u> 50 113 163 163	Events 1 34 35	<u>s Tota</u> 50 110 160) 2.8%) 97.2%	Risk Ratio <u>M-H. Fixed, 95% Cl</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80]	er platinum drugs cisplatin Risk Ratio M-H, Fixed, 95% Cl 0.01 0.1 1 10	
-	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	Z = 0.68 (P = 0.49) other platinum Events 1 1 16 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00)	a) drugs <u>Total</u> 50 113 163 1.58); I ² = 05)	Events 34 35 0%	s Tota 50 1 110 160) 2.8%) 97.2%	Risk Ratio <u>M-H. Fixed. 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe	er platinum drugs cisplatin Risk Ratio M-H. Fixed. 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin	
- F.	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting	Z = 0.68 (P = 0.49) other platinum Events 1 1 6 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum	a) drugs <u>Total</u> 50 113 163 1.58); I ² = 05) drugs	Events: 34 35 0% cispl	<u>s Tota</u> 50 110 160 5) 2.8%) 97.2%) 100.0 %	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting <u>Study or Subgroup</u>	Z = 0.68 (P = 0.49) other platinum Events 1 1 6 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum Events	o) drugs <u>Total</u> 50 113 163 0.58); I ² = 05) drugs <u>Total</u>	Events 1 34 35 0% cispl Events	<u>s Tota</u> 50 110 160 5) 2.8%) 97.2%) 100.0%	Risk Ratio <u>M-H. Fixed. 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H. Fixed, 95% CI</u>	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting <u>Study or Subgroup</u> Cao 2011	Z = 0.68 (P = 0.49) other platinum Events 1 1 16 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum Events 1	arright diameter is a second state of the s	Events 1 34 35 0% cispl Events 8	<u>s Tota</u> 50 110 160 5 5 5 5 5 5) 2.8%) 97.2%) 100.0% <u> Weight</u>) 20.7%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting <u>Study or Subgroup</u> Cao 2011 Hu 2016	Z = 0.68 (P = 0.49) other platinum Events 1 1 16 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum Events 1 2	a) drugs Total 50 113 163 1.58); l ² = 05) drugs Total 50 32	Events 34 35 0% cispl Events 8	s Tota 50 110 160 5 5 atin <u>5 Tota</u> 3 50 3 31) 2.8%) 97.2% 100.0% <u>I Weight</u>) 20.7% 7.9%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting <u>Study or Subgroup</u> Cao 2011 Hu 2016 Tang 2016	Z = 0.68 (P = 0.49) other platinum Events 1 1 16 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum Events 1 2 6	a) and the second se	Events 34 35 0% cispl Events 8 3 13	Tota 50 110 160 5 5 5 5 5 5 5 5 5 5) 2.8%) 97.2% 100.0% <u>100.0%</u> 20.7% 7.9%) 34.0%	Risk Ratio <u>M-H. Fixed. 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H. Fixed. 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61] 0.45 [0.18, 1.14]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia <u>Study or Subgroup</u> Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting <u>Study or Subgroup</u> Cao 2011 Hu 2016	Z = 0.68 (P = 0.49) other platinum Events 1 1 16 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum Events 1 2	a) drugs Total 50 113 163 1.58); l ² = 05) drugs Total 50 32	Events 34 35 0% cispl Events 8	Tota 50 110 160 5 5 5 5 5 5 5 5 5 5) 2.8%) 97.2% 100.0% <u>100.0%</u> 20.7% 7.9%) 34.0%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting Study or Subgroup Cao 2011 Hu 2016 Tang 2016 Zhan 2020	Z = 0.68 (P = 0.49) other platinum Events 1 1 16 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) other platinum Events 1 2 6	a) drugs Total 50 113 163 1.58); I ² = 05) drugs Total 50 32 113 113	Events 34 35 0% cispl Events 8 3 13	s Total 500 500 atin 500 s Total 3 500 3 310 3 1100 4 1100) 2.8%) 97.2%) 100.0% Weight) 20.7% 7.9%) 34.0% 3 37.4%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61] 0.45 [0.18, 1.14] 0.03 [0.00, 0.57]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting Study or Subgroup Cao 2011 Hu 2016 Tang 2016 Zhan 2020 Total (95% CI)	Z = 0.68 (P = 0.45) other platinum Events 1 1 6 17 0.30, df = 1 (P = 0.00) Z = 2.81 (P = 0.00) other platinum Events 1 2 6 0	a) and the second se	Events 1 34 35 0% cispl Events 8 3 13 14	s Total 500 500 atin 500 s Total 3 500 3 311 3 1100 4 113 3 304) 2.8%) 97.2% 100.0% <u>100.0%</u> 20.7% 7.9%) 34.0%	Risk Ratio <u>M-H. Fixed. 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H. Fixed. 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61] 0.45 [0.18, 1.14]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting Study or Subgroup Cao 2011 Hu 2016 Tang 2016 Zhan 2020 Total (95% CI) Total events	Z = 0.68 (P = 0.45) other platinum Events 1 16 17 0.30, df = 1 (P = 0.00) C = 2.81 (P = 0.00) other platinum Events 1 2 6 0 9	a) drugs Total 50 113 163 (.58); l ² = 55) drugs Total 50 32 113 113 113 308	Events 1 34 0% cispl Events 1 1 1 14	s Total 500 500 atin 500 s Total 3 500 3 311 3 1100 4 113 3 304) 2.8%) 97.2%) 100.0% Weight) 20.7% 7.9%) 34.0% 3 37.4%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61] 0.45 [0.18, 1.14] 0.03 [0.00, 0.57]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	
- F.	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting Study or Subgroup Cao 2011 Hu 2016 Tang 2016 Zhan 2020 Total (95% CI) Total events Heterogeneity: Chi ² =	Z = 0.68 (P = 0.49) other platinum Events 1 1 6 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) 0ther platinum Events 1 2 6 0 5.19, df = 3 (P = 0.00)	a) drugs Total 50 113 163 1.58); I ² = 05) drugs Total 50 32 113 113 308 1.16); I ² =	Events 1 34 0% cispl Events 1 1 1 14	s Total 500 500 atin 500 s Total 3 500 3 311 3 1100 4 113 3 304) 2.8%) 97.2%) 100.0% Weight) 20.7% 7.9%) 34.0% 3 37.4%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61] 0.45 [0.18, 1.14] 0.03 [0.00, 0.57]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 4 4 4 4 4 4 4 4 4 4 4 4 4	100
- F.	Test for overall effect: Anemia Study or Subgroup Cao 2011 Tang 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Vomiting Study or Subgroup Cao 2011 Hu 2016 Tang 2016 Zhan 2020 Total (95% CI) Total events	Z = 0.68 (P = 0.49) other platinum Events 1 1 6 17 0.30, df = 1 (P = 0.20) Z = 2.81 (P = 0.00) 0ther platinum Events 1 2 6 0 5.19, df = 3 (P = 0.00)	a) drugs Total 50 113 163 1.58); I ² = 05) drugs Total 50 32 113 113 308 1.16); I ² =	Events 1 34 0% cispl Events 1 1 1 14	s Total 500 500 atin 500 s Total 3 500 3 311 3 1100 4 113 3 304) 2.8%) 97.2%) 100.0% Weight) 20.7% 7.9%) 34.0% 3 37.4%	Risk Ratio <u>M-H, Fixed, 95% CI</u> 1.00 [0.06, 15.55] 0.46 [0.27, 0.78] 0.47 [0.28, 0.80] othe Risk Ratio <u>M-H, Fixed, 95% CI</u> 0.13 [0.02, 0.96] 0.65 [0.12, 3.61] 0.45 [0.18, 1.14] 0.03 [0.00, 0.57] 0.24 [0.12, 0.49]	er platinum drugs cisplatin Risk Ratio M-H. Fixed, 95% Cl 0.01 0.1 1 10 er platinum drugs cisplatin Risk Ratio	

effect on chemotherapy. In addition, nedaplatin-based CCRT is an effective and safe treatment for patients with stage II–IVB NPC, indicating that nedaplatin may be a promising alternative to cisplatin [15, 29]. In a randomized phase III trial, Mai et al. [16] showed that for patients with stages II–IVB NPC, nedaplatin-based CCRT was not inferior to cisplatin-based CCRT with respect to the 2-year PFS. Subsequent comments [30] indicate that it is too early to conclude that nedaplatin will replace cisplatin. However, the newly published results of the 5-year follow-up still support the results of the initial report [17].

Lobaplatin is a third-generation platinum drug. In previous studies, lobaplatin was found to overcome some forms of multiple drug resistance caused by other platinum-based drugs, such as cisplatin or carboplatin [8]. A random non-inferiority trial showed that lobaplatinbased induction chemotherapy plus CCRT has similar survival outcomes and side effect profiles as cisplatinbased therapy and thus may act as a promising alternative [14]. Clinical studies, such as ChiCTR1900021536 and ChiCTR-IIR-17013112, are ongoing and aim to further assess the benefits and risks of lobaplatin for NPC and verify the value of these treatment strategies.

Cisplatin has a lower drug price than platinum derivatives; however, it also has more symptomatic adverse events that require additional treatment processes, such as hydration and antiemetic preconditioning, and this increases the cost of treatment accordingly [31]. Liao et al. [10] found that nedaplatin is an advantageous and low-cost alternative to concurrent chemoradiotherapy for stage II-IVB NPC, based on a cost-benefit curve analysis. Lv et al. [14] mentioned that in south China, an area with high incidence of NPC, although the price of a new generation of platinum derivatives is higher than that of cisplatin, various chemotherapy drugs (such as lobaplatin) are included in the list of essential drugs under China's medical insurance system, and the supply of generic drugs reduces the cost [32]. However, the limited number of inpatient beds and the length of stay pose challenges. Patients waiting for hospital treatment may experience disease progression and have increased psychological stress. Shorter hospital stays with cisplatin derivatives may help alleviate these problems.

We conducted this meta-analysis to evaluate the efficacy and safety of other platinum-based chemotherapies versus cisplatin-based chemotherapy for locally advanced NPC. Choi et al. [33] performed a network meta-analysis on the efficacy of different neoadjuvant chemotherapeutic strategies in the treatment of NPC. The results showed that some cisplatin-based neoadjuvant chemotherapy regimens improved the prognosis of patients with NPC and reduced the toxicity of chemotherapy. However, the optimal neoadjuvant chemotherapy protocol is not fully consistent in terms of survival and efficiency. Yuan et al. [34] showed that the induction chemotherapy regimen, gemcitabine plus cisplatin, shows better performance in terms of survival outcomes. To date, there is no meta-analysis to adequately demonstrate differences in the efficacy of various platinum-based regimens in locally advanced NPC. To reduce bias, we selected RCTs that are clinically registered as eligible studies. Our meta-analysis revealed that there was no significant difference between other platinumbased and cisplatin-based chemotherapy in terms of OS, PFS, DMFS, and LRFS. Severe acute hematological side effects (\geq grade 3) such as neutropenia, leukopenia and thrombocytopenia were observed after platinum-based induction chemotherapy or throughout the treatment period; however, such side effects were equivalent to those in the cisplatin treatment group. It is worth noting that the risk of anemia was higher in patients receiving other platinum-based treatments. In contrast, the risk of non-hematological side effects such as nausea, vomiting, and weight loss after induction chemotherapy or during the whole treatment period was higher in the cisplatin treatment group. There was no difference in other non-hematological side effects, such as xerostomia, dermatitis, mucositis, and elevated levels of aminotransferase, between the two groups. Moreover, there was no significant difference in the late side effects such as xerostomia, subcutaneous fibrosis, hearing impairment, trismus, cranial nerve palsy and temporal lobe necrosis between the two groups. The studies included in this meta-analysis did not report any treatment-related disability or death.

The main limitation of this meta-analysis is that some of the studies included were not RCTs, which may affect our research outcomes. Moreover, most studies were conducted in China, which may be a source of potential bias. In addition, there are differences in the specific study populations, combined treatment schemes and treatment durations, which may affect further data analyses. Finally, the DNA level of EB virus is a prognostic factor for NPC, however, the included studies could not be analyzed by subgroups to address this factor.

Conclusion

Based on the systematic review and meta-analysis of the included studies, other platinum-based chemotherapy regimens were not inferior to cisplatin-based regimens and could be effective alternatives to cisplatin for the treatment of locally advanced NPC. Since most eligible studies were conducted in endemic areas, high-level evidence is needed to verify these findings in the future.

Abbreviations

NPC: Nasopharyngeal carcinoma; RCT: Randomized controlled trials; IC: Induction chemotherapy; CCRT: Concurrent chemoradiotherapy; AC: Adjuvant chemotherapy; Con: Control group (cisplatin-based group); Experimental group (other platinum-based group); NA: Not available; Re: Retrospetive study; NR: Not reported; FE: Fail to extract; 5FU: 5-Fluorouracil; OS: Overall survival; PFS: Progressive-free survival; DMFS: Distant metastasis-free survival; LRFS: Locoregional relapse-free survival.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09712-z.

Additional file 1.

Acknowledgements

We thank the members in the Min Kang's workgroup for helping to improve the grammar and spelling.

Authors' contributions

ZL and CL wrote the manuscript. DY, JS and TL performed the data search and data analysis. ZZ and LZ prepared figures. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 71964003, 71964003, 81760542, 82160467), the Natural Science Foundation of Guangxi Zhuang Autonomous Region (No.2018JJA141048), the Research Foundation of the Science and Technology Department of Guangxi Province, China (grant No.2016GXNSFAA380252, 2018AB61001 and 2019GXNSFAA185040), the Research Foundation of the Health Department of Guangxi Province, China (No.S2018087), Guangxi Medical University Training Program for Distinguished Young Scholars (2017), Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University (2016). Guangxi Medical High-level Talents Training Program.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Author details

¹Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning 530021, Guangxi, People's Republic of China. ²Guangxi Tumor Radiation Therapy Clinical Medical Research Center, Nanning, Guangxi, People's Republic of China. ³Department of Oncology, Sichuan Provincial People's Hospital-Qionglai Medical Center Hospital, Chengdu, Sichuan, People's Republic of China. ⁴Department of Obstetrics and Gynecology, Sichuan Provincial People's Hospital-Qionglai Medical Center Hospital, Chengdu, Sichuan, People's Republic of China. ⁵The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Center for Disease Prevention and Control, Liuzhou, Guangxi, People's Republic of China.

Received: 12 March 2022 Accepted: 23 May 2022 Published online: 06 June 2022

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
- Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80.
- Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.
- Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–92.
- Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163–71.
- Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219(3):177–86.
- Fung C, Dinh PJ, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Adv Urol. 2018;2018:8671832.
- McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001;10(1):119–28.
- Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48(10):1038–44.
- Liao W, Huang J, Wu Q, Zhu G, Wang X, Wen F, Zhang P, Zhang N, Li Q. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis. Oral Oncol. 2019;93:15–20.
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
- 14. Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):716–26.
- Tang C, Wu F, Wang R, Lu H, Li G, Liu M, Zhu H, Zhu J, Zhang Y, Hu K. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial. Am J Cancer Res. 2016;6(9):2064–75.
- Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, Qi B, Tang QN, Wang P, Li XY, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, noninferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(4):461–73.
- Tang QN, Liu LT, Qi B, Guo SS, Luo DH, Sun R, Sun XS, Chen DP, Guo L, Mo HY, et al. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021;4(12):e2138470.
- Hu Y, Fu JT, Shi D, Feng B, Shi Z. Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma. J Cancer Res Ther. 2016;12(Supplement):C252–5.

- Liu T, Sun Q, Chen J, Li B, Qin W, Wang F, Ye Z, Hu F. Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study. J Cancer. 2018;9(20):3676–82.
- Zhan Z, Tao H, Qiu W, Liu Z, Zhang R, Liao K, Li G, Yuan Y, Yuan T, Zheng R. Clinical value of nedaplatin-based chemotherapy combined with radiotherapy for locoregional advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. J Cancer. 2020;11(23):6782–9.
- Cao K, Zhang A, Ma W, Huang P, Luo D, Xia W. Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study. Chin J Oncol. 2011;33(1):50–2.
- Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V, Ford J. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer. 2007;43(9):1399–406.
- Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.
- 24. Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–95.
- Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55.
- Ribassin-Majed L, Marguet S, Lee A, Ng WT, Ma J, Chan A, Huang PY, Zhu G, Chua D, Chen Y, et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. J Clin Oncol. 2017;35(5):498–505.
- Frikha M, Auperin A, Tao Y, Elloumi F, Toumi N, Blanchard P, Lang P, Sun S, Racadot S, Thariat J, et al. A randomized trial of induction docetaxelcisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006–02). ANN ONCOL. 2018;29(3):731–6.
- Yau TK, Lee AW, Wong DH, Pang ES, Ng WT, Yeung RM, Soong IS. Treatment of Stage IV(A-B) nasopharyngeal carcinoma by inductionconcurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys. 2006;66(4):1004–10.
- Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C, Zhang Z, Li Q, Xu W, Li Z, et al. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol. 2010;40(5):425–31.
- Blanchard P, Tao Y. Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts? Lancet Oncol. 2018;19(4):429–31.
- Blower PR. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer. 1990;26(Suppl 1):S8–11.
- National Healthcare Security Administration. http://www.nhsa.gov.cn (Accessed 25 Nov 2020).
- Choi HC, Chan SK, Lam KO, Chan SY, Chau SC, Kwong DL, Leung TW, Luk MY, Lee AW, Lee VH. The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis. Front Oncol. 2021;11:626145.
- Yuan C, Xu XH, Luo SW, Wang L, Sun M, Ni LH, Xu L, Wang XL, Zeng G. Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?: A network metaanalysis. Medicine (Baltimore). 2018;97(34):e11978.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

